The increased activation and expression of ERK5 have been implicated in the pathophysiology of a wide range of cancers (Sanchez-Fdez et al., 2021), suggesting the potential therapeutic value of depleting or pharmacologically inhibiting ERK5 in inflammation and tumorigenesis. This evidence concerns the gene MAPK7 and cancer.